» Articles » PMID: 37792075

Behavioral Treatment for Speech and Language in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech: A Systematic Review

Abstract

Primary progressive aphasia (PPA) and primary progressive apraxia of speech (PPAOS) are neurodegenerative syndromes characterized by progressive decline in language or speech. There is a growing number of studies investigating speech-language interventions for PPA/PPAOS. An updated systematic evaluation of the treatment evidence is warranted to inform best clinical practice and guide future treatment research. We systematically reviewed the evidence for behavioral treatment for speech and language in this population. Reviewed articles were published in peer-reviewed journals through 31 May 2021. We evaluated level of evidence, reporting quality, and risk of bias using a modified version of the American Speech-Language Hearing Association (ASHA) Levels of Evidence, an appraisal point system, additional reporting quality and internal/external validity items, and, as appropriate, the Single Case Experimental Design Scale or the Physiotherapy Evidence Database - PsycBITE Rating Scale for Randomized and Non-Randomized Controlled Trials. Results were synthesized using quantitative summaries and narrative review. A total of 103 studies reported treatment outcomes for 626 individuals with PPA; no studies used the diagnostic label PPAOS. Most studies evaluated interventions for word retrieval. The highest-quality evidence was provided by 45 experimental and quasi-experimental studies (16 controlled group studies, 29 single-subject designs). All (k = 45/45) reported improvement on a primary outcome measure; most reported generalization (k = 34/43), maintenance (k = 34/39), or social validity (k = 17/19) of treatment for at least one participant. The available evidence supports speech-language intervention for persons with PPA; however, treatment for PPAOS awaits systematic investigation. Implications and limitations of the evidence and the review are discussed.

Citing Articles

Advancing Neuropsychological Rehabilitation in Primary Progressive Aphasia Based on Principles of Cognitive Neuroscience: A Scoping Review and Systematic Analysis of the Data.

Gkintoni E, Michou E Brain Sci. 2025; 14(12).

PMID: 39766433 PMC: 11727489. DOI: 10.3390/brainsci14121234.


Assessment of disease impact through health-related quality of life measurement in primary progressive aphasia.

Hopkins T, Kwon E, Lapins A, Gill N, Roberts A, Rogalski E Alzheimers Dement (N Y). 2025; 10(4):e12499.

PMID: 39748847 PMC: 11694525. DOI: 10.1002/trc2.12499.


Communication Bridge-2 randomized controlled trial: Recruitment and baseline features.

Rogalski E, Bona M, Esparza M, Mooney A, Fried-Oken M, Rademaker A Alzheimers Dement. 2024; 21(1):e14168.

PMID: 39588869 PMC: 11771146. DOI: 10.1002/alz.14168.


An international core outcome set for primary progressive aphasia (COS-PPA): Consensus-based recommendations for communication interventions across research and clinical settings.

Volkmer A, Alves E, Bar-Zeev H, Barbieri E, Battista P, Beales A Alzheimers Dement. 2024; 21(1):e14362.

PMID: 39535361 PMC: 11781257. DOI: 10.1002/alz.14362.


Effects of Modified Video-Implemented Script Training for Aphasia in the Three Variants of Primary Progressive Aphasia.

Montagut N, Borrego-Ecija S, Herrero J, Castellvi M, Balasa M, Llado A J Speech Lang Hear Res. 2024; 67(10):3762-3777.

PMID: 39302879 PMC: 11482574. DOI: 10.1044/2024_JSLHR-23-00583.


References
1.
Wauters L, Croot K, Dial H, Duffy J, Grasso S, Kim E . Behavioral Treatment for Speech and Language in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech: A Systematic Review. Neuropsychol Rev. 2023; 34(3):882-923. PMC: 11473583. DOI: 10.1007/s11065-023-09607-1. View

2.
Mesulam M . Primary progressive aphasia. Ann Neurol. 2001; 49(4):425-32. View

3.
Taylor-Rubin C, Nickels L, Croot K . Exploring the effects of verb and noun treatment on verb phrase production in primary progressive aphasia: A series of single case experimental design studies. Neuropsychol Rehabil. 2021; 32(6):1121-1163. DOI: 10.1080/09602011.2021.1879174. View

4.
Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K . The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. Int J Geriatr Psychiatry. 2015; 31(8):892-904. PMC: 6084309. DOI: 10.1002/gps.4405. View

5.
Tsai R, Boxer A . Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016; 138 Suppl 1:211-21. PMC: 5217534. DOI: 10.1111/jnc.13640. View